Biotech Values

[DewDiligence]

Nestle invests additional $200M in AIMT:

https://www.reuters.com/article/us-aimmune-nestle-stake/nestle-invests-200-million-more-in-aimmune-after-peanut-allergy-drug-approval-idUSKBN1ZZ1VX

Nestle has been trying to become a “nutrition, health and wellness” company, with its Nestle Health Science unit playing a pivotal role, as packaged food sales slow amid changing tastes.

The unit invested $145 million in Aimmune in 2016, followed by $30 million as part of the drugmaker’s public offering in February 2018, and another $98 million in November 2018.

Aimmune would use the latest Nestle investment to fund the launch of Palforzia, which is the first approved therapy for reducing and potentially eliminating allergic reactions to peanuts in children.